Publicaciones en las que colabora con José A. Obeso Inchausti (68)

2012

  1. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation

    Movement Disorders, Vol. 27, Núm. 1, pp. 146-150

2011

  1. LINGO1 gene analysis in Parkinson's disease phenotypes

    Movement Disorders, Vol. 26, Núm. 4, pp. 722-727

2010

  1. Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population

    European Journal of Neurology, Vol. 17, Núm. 2, pp. 321-325

2009

  1. New MRI, 18F-DOPA and 11C-(+)-α-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: Advantages to improve PET quantification

    NeuroImage, Vol. 47, Núm. 2, pp. 533-539

2005

  1. Optimization of use of levodopa in Parkinson's disease: Role of levodopa-carbidopa-entacapone combination

    Neurologia, Vol. 20, Núm. 4, pp. 180-188

1996

  1. Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

    Neurology, Vol. 47, Núm. 1, pp. 219-224

  2. Consequences of nigrostriatal denervation on the γ-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes

    Neurology, Vol. 46, Núm. 3, pp. 802-809

  3. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.

    Advances in neurology, Vol. 69, pp. 209-216

  4. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis

    Brain, Vol. 119, Núm. 5, pp. 1717-1727

1995

  1. Effects of Nigrostriatal Denervation and L‐Dopa Therapy on the GABAergic Neurons of the Striatum in MPTP‐treated Monkeys and Parkinson's Disease: An In Situ Hybridization Study of GAD67 mRNA

    European Journal of Neuroscience, Vol. 7, Núm. 6, pp. 1199-1209

  2. Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum

    Neuroscience, Vol. 68, Núm. 4, pp. 1189-1198

  3. Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain

    Experimental Neurology, Vol. 131, Núm. 1, pp. 108-113

  4. The rationale for the use of dopamine agonists in parkinson's disease

    Neurology, Vol. 45, Núm. 3, pp. S6-S12

1994

  1. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP–intoxicated monkeys: Effect of levodopa and GM1 ganglioside therapy

    Annals of Neurology, Vol. 36, Núm. 2, pp. 206-214

  2. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration

    Neuroscience Letters, Vol. 175, Núm. 1-2, pp. 121-125

  3. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

    Journal of Neurology Neurosurgery and Psychiatry, Vol. 57, Núm. 5, pp. 562-566

  4. Subthalamotomy improves MPTP-lnduced parkinsonism in monkeys

    Stereotactic and Functional Neurosurgery, Vol. 62, Núm. 1-4, pp. 98-102

1993

  1. Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys

    Journal of the Neurological Sciences, Vol. 114, Núm. 1, pp. 40-44

  2. Clinical, kinetic, pharmacodynamic and endocrinological studies in parkinsonian patients with subcutaneous lisuride infusion

    New Trends in Clinical Neuropharmacology, Vol. 7, Núm. 4, pp. 155-165

  3. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?

    Neuroscience, Vol. 56, Núm. 2, pp. 499-511